The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
28-Jun-05
$111 million
Target:
Texas Genco LLC
Acquiror:
Kinder Morgan Energy Partners LP
Advised Texas Genco LLC on the sale of natural gas storage assets to Kinder Morgan Energy Partners LP
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
19-Apr-22
Pending
$107 million
Target:
Syrah Resources
Acquiror:
U.S. Department of Energy
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
15-Jul-05
$70 million
Target:
Texas Genco LLC
Acquiror:
TEPPCO Partners LP
Advised Texas Genco LLC on the sale of a fuel oil pipeline and associated storage assets to TEPPCO Partners LP
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
02-Mar-11
$NA
Target:
TSmarine
Acquiror:
Fugro N.V.
Advised CHAMP Ventures on the sale of its portfolio company TSmarine, a provider of subsea services to the offshore oil and gas industry, to Fugro, among the world's leading service providers for the collection and interpretation of data relating to the earth's surface and sub-surface and for associated services
01-Jul-19
$NA
Target:
Alloy Piping Products (“APP”)
Acquiror:
N/A
Advised McDermott International, a premier, fully integrated provider of technology, engineering and construction solutions to the energy industry, on the sale of Alloy Piping Products (“APP”), the distribution and manufacturing arm of its US pipe fabrication business
10-Aug-06
$NA
Target:
Forest City Ratner
Acquiror:
Forest City Enterprises Inc.
Advised Forest City Enterprises, Inc. on the restructuring of its business relationship with its New York City affiliate Forest City Ratner
30-Jun-06
$NA
Target:
Topaz Power Partners
Acquiror:
Carlyle / Riverstone
(portfolio of seven power plants)
Advised Topaz Power Partners (a joint venture of Sempra Energy and Carlyle / Riverstone) on the sale of a portfolio of seven power plants to an affiliate of Carlyle / Riverstone
19-Dec-14
$NA
Target:
NYK Ports LLC
Acquiror:
Macquarie Infrastructure Partners
Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund
22-Jul-19
$NA
Target:
EnerVest properties in the Utica Shale
Acquiror:
Encino Acquisition Partners
Advised EnerVest Ltd., and its associated investment partnerships, on the sale of Utica Shale oil and gas properties across 12 counties in eastern Ohio to an entity controlled by Encino Acquisition Partners
21-Dec-23
Undisclosed
Target:
Exit of Homesafe Equity Release Joint Venture
Acquiror:
Athy Pty Ltd
Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
30-Nov-18
$NA
Target:
Aisthesis
Acquiror:
NAPA Management Services Corporation
Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
11-Jul-05
$NA
Target:
Inergy, L.P.
Acquiror:
Inergy Holdings GP, LLC
Provided a fairness opinion to Inergy Holdings GP, LLC regarding the Stagecoach natural gas storage acquisition
11-Oct-19
$NA
Target:
Olifant Energy, LLC
Acquiror:
U.S. Energy Development Corporation
Advised US Energy Development Corporation, a Texas-based, privately held oil and gas operator, on its acquisition of Olifant Energy Corporation, a Tulsa-based E&P company with operations in Ward County of the Delaware Basin
05-May-22
Undisclosed
Target:
Airtower Networks
Acquiror:
DIF Capital Partners
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives